Related Experiment Video
Updated: Jun 11, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Tepotinib-Induced Cholangitis in a Patient With Non-Small Cell Lung Cancer: A Case Report
Yoshimasa Hachisu1, Kojiro Yoshida1, Yuki Hosino1
1Department of Respiratory Medicine Maebashi Red Cross Hospital Maebashi Japan.
Abstract:
Tepotinib, a mesenchymal epithelial transition factor (MET) tyrosine kinase inhibitor, is used to treat non-small cell lung cancer with MET exon 14 skipping mutations. Although hepatotoxicity has been reported, drug-induced cholangitis has not been reported before. Here, we report a case of tepotinib-induced cholangitis in a 77-year-old woman with preexisting primary biliary cholangitis. During tepotinib treatment, the patient experienced abdominal pain along with elevated hepatobiliary enzyme levels. Imaging and histological examinations revealed findings similar to sclerosing cholangitis. The liver enzyme levels decreased after drug discontinuation. This case highlights the need for careful monitoring of hepatobiliary function when prescribing MET inhibitors, particularly in patients with underlying liver disease.
Insights
Tepotinib, a MET inhibitor for lung cancer, may cause cholangitis, a rare bile duct inflammation. Careful liver monitoring is crucial, especially in patients with existing liver conditions.
Area of Science:
- Oncology
- Hepatology
- Pharmacology
Background:
- Tepotinib is a MET tyrosine kinase inhibitor for non-small cell lung cancer with MET exon 14 skipping mutations.
- Hepatotoxicity is a known side effect of tepotinib, but drug-induced cholangitis has not been previously reported.
- Primary biliary cholangitis is a chronic liver disease affecting bile ducts.
Purpose of the Study:
- To report a novel case of tepotinib-induced cholangitis.
- To emphasize the importance of monitoring hepatobiliary function during tepotinib treatment.
- To highlight potential risks in patients with pre-existing liver conditions.
Main Methods:
- Case report of a 77-year-old woman with primary biliary cholangitis treated with tepotinib.
- Clinical monitoring of abdominal pain and hepatobiliary enzyme levels.
- Diagnostic evaluation including imaging and histological examination.
Main Results:
- The patient developed symptoms consistent with cholangitis during tepotinib therapy.
- Imaging and histology showed findings similar to sclerosing cholangitis.
- Hepatobiliary enzyme levels normalized after discontinuing tepotinib.
Conclusions:
- Tepotinib may induce cholangitis, a previously unreported adverse event.
- Close monitoring of liver function is essential for patients receiving tepotinib.
- Caution is advised when prescribing MET inhibitors to patients with underlying liver diseases like primary biliary cholangitis.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
